Loss of IGF2 imprinting: A potential marker of colorectal cancer risk

Hengmi Cui; Marcia Cruz-Correa; Francis M. Giardiello; David F. Hutcheon; David R. Kafonek; Sheri Brandenburg; Yiqian Wu; Xiaobing He; Neil R. Powe; Andrew P. Feinberg

doi:10.1126/science.1080902

Loss of IGF2 imprinting: A potential marker of colorectal cancer risk

Hengmi Cui, Marcia Cruz-Correa, Francis M. Giardiello, David F. Hutcheon, David R. Kafonek, Sheri Brandenburg, Yiqian Wu, Xiaobing He, Neil R. Powe, Andrew P. Feinberg

School of Medicine

Research output: Contribution to journal › Article › peer-review

617 Scopus citations

Abstract

Loss of imprinting (LOI), an epigenetic alteration affecting the insulin-like growth factor II gene (IGF2), is found in normal colonic mucosa of about 30% of colorectal cancer (CRC) patients, but it is found in only 10% of healthy individuals. In a pilot study to investigate the utility of LOI as a marker of CRC risk, we evaluated 172 patients at a colonoscopy clinic. The adjusted odds ratio for LOI in lymphocytes was 5.15 for patients with a positive family history [95% confidence interval (95% CI), 1.70 to 16.96; probability P = 0.002], 3.46 for patients with adenomas (95% Cl, 1.14 to 11.37; P = 0.026), and 21.7 for patients with CRC (95% Cl, 3.48 to 153.6; P = 0.0005). LOI can be assayed with a DNA-based blood test, and it may be a valuable predictive marker of an individual's risk for CRC.

Original language	English (US)
Pages (from-to)	1753-1755
Number of pages	3
Journal	Science
Volume	299
Issue number	5613
DOIs	https://doi.org/10.1126/science.1080902
State	Published - Mar 14 2003

ASJC Scopus subject areas

General

Access to Document

10.1126/science.1080902

Cite this

@article{5fb67582e8ba4ee59e5709c7cd8ff478,

title = "Loss of IGF2 imprinting: A potential marker of colorectal cancer risk",

abstract = "Loss of imprinting (LOI), an epigenetic alteration affecting the insulin-like growth factor II gene (IGF2), is found in normal colonic mucosa of about 30% of colorectal cancer (CRC) patients, but it is found in only 10% of healthy individuals. In a pilot study to investigate the utility of LOI as a marker of CRC risk, we evaluated 172 patients at a colonoscopy clinic. The adjusted odds ratio for LOI in lymphocytes was 5.15 for patients with a positive family history [95% confidence interval (95% CI), 1.70 to 16.96; probability P = 0.002], 3.46 for patients with adenomas (95% Cl, 1.14 to 11.37; P = 0.026), and 21.7 for patients with CRC (95% Cl, 3.48 to 153.6; P = 0.0005). LOI can be assayed with a DNA-based blood test, and it may be a valuable predictive marker of an individual's risk for CRC.",

author = "Hengmi Cui and Marcia Cruz-Correa and Giardiello, {Francis M.} and Hutcheon, {David F.} and Kafonek, {David R.} and Sheri Brandenburg and Yiqian Wu and Xiaobing He and Powe, {Neil R.} and Feinberg, {Andrew P.}",

year = "2003",

month = mar,

day = "14",

doi = "10.1126/science.1080902",

language = "English (US)",

volume = "299",

pages = "1753--1755",

journal = "Science",

issn = "0036-8075",

publisher = "American Association for the Advancement of Science",

number = "5613",

}

TY - JOUR

T1 - Loss of IGF2 imprinting

T2 - A potential marker of colorectal cancer risk

AU - Cui, Hengmi

AU - Cruz-Correa, Marcia

AU - Giardiello, Francis M.

AU - Hutcheon, David F.

AU - Kafonek, David R.

AU - Brandenburg, Sheri

AU - Wu, Yiqian

AU - He, Xiaobing

AU - Powe, Neil R.

AU - Feinberg, Andrew P.

PY - 2003/3/14

Y1 - 2003/3/14

N2 - Loss of imprinting (LOI), an epigenetic alteration affecting the insulin-like growth factor II gene (IGF2), is found in normal colonic mucosa of about 30% of colorectal cancer (CRC) patients, but it is found in only 10% of healthy individuals. In a pilot study to investigate the utility of LOI as a marker of CRC risk, we evaluated 172 patients at a colonoscopy clinic. The adjusted odds ratio for LOI in lymphocytes was 5.15 for patients with a positive family history [95% confidence interval (95% CI), 1.70 to 16.96; probability P = 0.002], 3.46 for patients with adenomas (95% Cl, 1.14 to 11.37; P = 0.026), and 21.7 for patients with CRC (95% Cl, 3.48 to 153.6; P = 0.0005). LOI can be assayed with a DNA-based blood test, and it may be a valuable predictive marker of an individual's risk for CRC.

AB - Loss of imprinting (LOI), an epigenetic alteration affecting the insulin-like growth factor II gene (IGF2), is found in normal colonic mucosa of about 30% of colorectal cancer (CRC) patients, but it is found in only 10% of healthy individuals. In a pilot study to investigate the utility of LOI as a marker of CRC risk, we evaluated 172 patients at a colonoscopy clinic. The adjusted odds ratio for LOI in lymphocytes was 5.15 for patients with a positive family history [95% confidence interval (95% CI), 1.70 to 16.96; probability P = 0.002], 3.46 for patients with adenomas (95% Cl, 1.14 to 11.37; P = 0.026), and 21.7 for patients with CRC (95% Cl, 3.48 to 153.6; P = 0.0005). LOI can be assayed with a DNA-based blood test, and it may be a valuable predictive marker of an individual's risk for CRC.

UR - http://www.scopus.com/inward/record.url?scp=0037436509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037436509&partnerID=8YFLogxK

U2 - 10.1126/science.1080902

DO - 10.1126/science.1080902

M3 - Article

C2 - 12637750

AN - SCOPUS:0037436509

SN - 0036-8075

VL - 299

SP - 1753

EP - 1755

JO - Science

JF - Science

IS - 5613

ER -

Loss of IGF2 imprinting: A potential marker of colorectal cancer risk

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this